Skip to content
CRBio

Catalyzing Innovation Hyderabad · Est. 2007

Delivering excellence. Building trust.

CRBio — A trusted partner delivering integrated BA/BE solutions with accountability, quality and scientific precision.

A division of Chromo laboratories India Private Limited.

Regulators & frameworks we align with

Regulatory submissions

1000+ BA/BE studies completed and submitted across major regulatory bodies, including US FDA, MHRA, EMA, WHO, Health Canada, CDSCO and other national authorities.

Marks are shown for context on programme geographies; ownership remains with each agency. Brochure-aligned artwork—swap for separately cleared assets if required.

Why CRBio

  • An integrated, accountable team managing your study end-to-end
  • State-of-the-art clinical and bioanalytical capabilities
  • Expertise in PK analysis, biostatistics and data management
  • Single-point accountability with transparent communication
  • Quality, compliance and timely delivery backed by 19+ years of experience
Company profile

Bioanalytics & storage

9 LC‑MS systems with HPLC routes; eight −86 °C freezers; Eurotherm 21 CFR Part 11 temperature governance.

Clinical capacity

4 independent clinical pharmacology units with 114‑bed unit; twin functional ICUs (3 beds each); male & female volunteer programmes; speciality populations & patient PK pathways.

Regulatory & dossier coherence

1000+ BA/BE studies completed and lodged with major regulators—programme leadership that respects inspection cadence.

CRBio campus, Hyderabad

Throughput without compromising traceability

Clinical research timelines are relentless—we organise sample logistics, QA touchpoints and documentation so exploratory science still meets filing discipline.

Capability

Our strength and expertise

We assure high-throughput sample analysis and quick turnaround times for challenging molecules. Our team blends young energy with deep domain expertise and regulatory judgement.

The library now spans 300+ validated methods—from simple and simultaneous assays through ultra-low LLOQ work, chiral and derivatisation strategies, and speciality matrices.

Experience footprint

  • Studies on controlled substances
  • Psychotropic substances
  • Post-menopausal female cohorts
  • Hormonal drugs
  • Patch studies
  • 505(b)(2) pathway
  • First-to-file experience
  • PD study experience (Orlistat)
  • PK endpoint studies — azathioprine, nevirapine, temozolomide, clozapine, capecitabine

Next step

Route your brief to BD or programmes

Postal address and telephone are listed on our Contact page and in the site footer. For a quick route in, email info@crbio.co.in.